Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Diluted EPS of $18.15 per share (loss) for fiscal year 2024.
CERO THERAPEUTICS HOLDINGS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$18.15 | +81.5% |
| 2024 | -$97.90 | +92.2% |
| 2023 | -$1248.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.10 | +94.7% | +85.3% |
| June 30, 2025 | -$61.71 | +79.6% | -3781.1% |
| March 31, 2025 | -$1.59 | +87.0% | +99.1% |
| September 30, 2024 | -$170.22 | — | +43.7% |
| June 30, 2024 | -$302.32 | -131343.5% | -2369.9% |
| March 31, 2024 | -$12.24 | -4433.3% | +99.4% |
| January 31, 2024 | -$1959.63 | — | -851913.0% |
| June 30, 2023 | -$0.23 | — | +14.8% |
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +81.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2024 period, CERO THERAPEUTICS HOLDINGS, INC.’s diluted eps has grown by 98.5% (from $1248.64 per share (loss) to $18.15 per share (loss)).
- The most recent figure is from CERO THERAPEUTICS HOLDINGS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: